Q3 2025 · —
Revenue$0.00$0.00 no prior Q3 2024 on fileno prior Q2 2025 on file
Net Income-$33.48M-$33.48M no prior Q3 2024 on fileN/M vs Q2 2025
EPS Diluted-$21.66-$21.66 no prior Q3 2024 on fileN/M vs Q2 2025
Operating Income-$34,845,000—
Operating Cash Flowderived-$31,535,000—
Free Cash Flowderived-$31,628,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2024 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Parabilis Medicines, Inc. · CIK 1657677 · Engraved from SEC EDGAR